ImmuCell vs Trinity Biotech
ICCC and TRIB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ICCC and TRIB compare
ImmuCell grew revenue faster over the last twelve months (19.6% versus −28.9% for Trinity Biotech).
ImmuCell keeps more of each dollar of sales as profit, with a net margin of 5.7% compared with −85.4% at Trinity Biotech.
ImmuCell scores higher on the StockData Score (12 against 1 for Trinity Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ICCC | TRIB |
|---|---|---|
| Size and price | ||
| Market cap | $92.8M | – |
| Share price | $10.22 | $5.88 |
| Change, 1 year | 63.0% | −78.2% |
| Change, 5 years | 15.6% | −98.0% |
| Beta (5Y) | 0.10 | 1.43 |
| Employees | 73 | 287 |
| StockData Score | ||
| Total score | 12 (better) | 1 |
| Valuation score | 1 (better) | 0 |
| Growth score | 2 (better) | 1 |
| Performance score | 4 (better) | 0 |
| Health score | 5 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 51.1× | – |
| P/S | 2.8× | – |
| P/B | 2.8× | – |
| EV/EBITDA | 13.3× | – |
| P/FCF | 17.2× | – |
| FCF yield | 5.8% | – |
| Fair value | $8.80 | – |
| Margin of safety | −16.1% | – |
| Growth | ||
| Revenue growth (TTM) | 19.6% (better) | −28.9% |
| Revenue growth, 5Y average | 12.5% (better) | −15.6% |
| Net income growth (TTM) | −19.1% | – |
| EPS growth (TTM) | −23.1% | – |
| Profitability | ||
| Gross margin | 40.8% (better) | 38.6% |
| Operating margin | 14.5% (better) | −36.1% |
| Net margin | 5.7% (better) | −85.4% |
| FCF margin | 16.3% (better) | −13.7% |
| Return on equity | 6.0% | – |
| Return on invested capital | 13.8% | – |
| Financial health | ||
| Debt / equity | 0.24 | – |
| Net debt / EBITDA | −0.00 | – |
| Interest coverage | 12.2× (better) | −0.7× |
| Current ratio | 4.61 (better) | 0.25 |
| Altman Z-score | 4.81 | – |
| Piotroski F-score | 7 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | 0.00% | – |
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 14.7% | 0.01% |
| Held by insiders | 13.6% | 51.7% |
| Insider net buying, 12 months | $156K | – |
| Short interest, % of float | 0.19% | – |
Go deeper
- ICCC stock overview
- ICCC income statement
- ICCC valuation and score
- TRIB stock overview
- TRIB income statement
- TRIB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.